Measurement of plasma levels of isoniazid for dose adjustment in the hemodialysis patients

Tuberculosis remains a major public health pro­blem in the developing world, and the immune compromised patients receiving dialysis the­rapy are known to be at increased risk of tuber­culosis and occur primarily in extra-pulmonary sites. Isoniazid (INH), the hydrazide of isonico­tinic acid, is the primary drug prescribed for the treatment of active tuberculosis and the prophy­laxis of tuberculosis exposure. Mild, reversible hepatotoxicity is the most common adverse drug reaction associated with therapeutic do­sages.